肝细胞癌
肝硬化
高尔基体
肝纤维化
慢性肝炎
医学
胃肠病学
内科学
生物
免疫学
病毒
内质网
生物化学
作者
Y N Liu,Mingjie Yao,Shuai Zheng,X M Chen,X Y Liu,Peng Hu,Qishui Ou,Xiaoguang Dou,H S Chen,Zhongping Duan,Jinlin Hou,Yuemin Nan,Zhiliang Gao,Xiaoyuan Xu,Hui Zhuang,Fengmin Lu
出处
期刊:PubMed
日期:2022-01-20
卷期号:30 (1): 4-8
标识
DOI:10.3760/cma.j.cn501113-20210210-00084
摘要
Golgi protein 73 (GP73) is a transmembrane protein on the Golgi apparatus and can be cut and released into the blood. In recent years, an increasing number of clinical studies have shown that the elevated serum GP73 level is closely related to liver diseases. And thus GP73 is expected to be used as a new serum marker for assessing progress of chronic liver diseases. Herein, the clinical application of serum GP73 in chronic hepatitis, liver fibrosis, liver cirrhosis and hepatocellular carcinoma with different etiologies was reviewed based on available literatures; and a research outlook in this field is made.高尔基体蛋白73(GP73)是细胞高尔基体上的一种跨膜蛋白,可被切割释放入血。近年来,越来越多的临床研究表明,血清GP73的升高与肝脏疾病密切相关,有望作为评估慢性肝脏疾病进展的新型血清学标志物。现围绕血清GP73对不同病因引起的慢性肝炎、肝纤维化、肝硬化和肝细胞癌中的临床应用进行综述,并对未来研究进行展望。.
科研通智能强力驱动
Strongly Powered by AbleSci AI